Erika Smith - Director of the Blavatnik Fund for Innovation at Yale

Transcription

1 Erika Smith - Director of the Blavatnik Fund for Innovation at Yale erika.smith@yale.edu 1

2 GOAL: Advance Yale s biomedical technologies to the stage where they are ready for partnership (i.e. bridge the development gap ) SUCCESSFUL OUTCOMES: Startup formation Licenses to biotech and pharma Major industry-sponsored research agreements

3 The University Industry 3

4 Groundbreaking Yale Research Partnerable Technology Licensing Leads development ACCELERATOR ADVISORY COMMITTEE INDUSTRY (companies and VCs) IDENTIFY opportunities EVALUATE potential projects MANAGE projects PARTNER technologies /letter of intent (October ) Meet with OCR lead to develop preproposal in response to RFP Preproposal Submission (November 15, 2016) Full Proposal Submission (March 31, 2017) Develop detailed R&D plans based on industry input (IP/FTO, competitive landscape, market demand, technical risk, commercial strategy Form project teams Use outside consultants as needed technical, regulatory, other Monitor progress toward milestones, budget Additional patent filings Engage with potential industry partners and VCs Execute deals IP licensing, startup formation and other corporate partnerships Select Projects for Full proposal (Investment Advisory Board) Select Projects for Funding (Investment Advisory Board)

5 INVESTMENT ADVISORY BOARD Fred Cohen TPG Biotech Steve Knight F-Prime Capital Liam Ratcliffe New Leaf Venture Partners Jason Rhodes Atlas Venture Tim Shannon Canaan Partners 5 David Singer Maverick Ventures Steve Squinto Orbimed Mary Tanner Evolution Life Science Partners Peter L. Thoren Access Industries

6 Implementation Pilot Grants: $25K - $100k for 1 year Development Grants: $100K-$300k for 1-2 years Majority of project activities occur at contract research organizations (CRO) Selection criteria includes: Research addresses major unmet need Assignment of Yale IP Strong indications of commercial interest at the outset and clear roadmap for research, development and commercialization Funding will really shift the odds Potentially Patentable technology with no third party encumbrance (for example MTAs, option/license owed to company, joint ownership) Engaged, committed principal investigator 6

7 Examples of projects selected at Harvard 7

8 Therapeutic antibody to treat metabolic diseases Novel adipokine-targeting therapeutic antibody potential treatment of type 2 diabetes, obesity and complications associated with metabolic syndrome Prof. Gökhan Hotamisligil, Dept. of Genetics and Complex Diseases, Harvard TH Chan School of Public Health Blavatnik Biomedical Accelerator funded target validation and early efforts for antibody generation In vivo validation Humanization of mouse for the target adipokine Initial monoclonal Ab efforts License and collaboration ($7 million sponsored research) Pharma partner with expertise in therapeutic antibody development Integrated co-development model between the two organizations Drug candidate now at late stage of preclinical development

9 Platform for novel macrolide antibiotics (startup) Start-up based on platform technology for making macrolide antibiotics fully synthetic route enabling unprecedented modification of the macrolide scaffold fully synthetic route to macrolide antibiotics Professor Andrew Myers, Department of Chemistry and Chemical Biology (Faculty of Arts and Sciences) Blavatnik Biomedical Accelerator funded the platform development and synthesis of early product candidates Funded over a 2 year period Optimization of synthetic route Synthesis of hundreds of novel macrolide antibiotics Full-panel MIC in vitro testing in bacteria clinical macrolideresistant strains Startup: $22 million series A financing in 2015 Strong syndicate of VCs / strategic investors Partnered with Blavatnik Fellowship in Life Science Entrepreneurship at Harvard Business School, early involvement of a CEO candidate

10 Small molecule therapeutic for AML (license) First-in-class small molecule inhibitors of a novel target for treatment of hematological cancers with an initial focus on acute myeloid leukemia (AML) In vitro biology X-ray crystal structureguided drug optimization In vivo validation Professor Matthew Shair, Department of Chemistry and Chemical Biology (Faculty of Arts and Sciences) Blavatnik Biomedical Accelerator supported this technology from discovery through late preclinical stage Invested ~$1.5M over a 4 year period Large fraction of funding went to activities at CROs (~$1M) Accelerator also supported consultants (DMPK, tox, etc.) No federal funding was made available to develop this technology Exclusive license and collaboration agreement with Merck $20 million upfront, eligible for development and commercialization milestone payments, tiered royalties Three years of sponsored research funding for Shair lab

11 How to Get Started: KEY DATES Proposal Application + FAQs online Letter of Intent: Fri., Oct. 28, 2016 Pre-proposal submission deadline: Nov. 15, 2016 Full proposal submission deadline: March 31, 2017 Funding start date: June 30, QUESTIONS: yale.blavatnikfund@yale.edu CONNECTIONS: 11

12 INNOVATOR RESOURCES What we do: support faculty & student innovation Yale has 18,000+ Potential Innovators

13 Innovator Resources: Campus Partnerships Program in Innovative Therapies for CT Health (PITCH) pitch.yale.edu Center for Biomedical and Interventional Therapies (CBIT) cbit.yale.edu Yale Center for Clinical Investigation (YCCI) ycci.yale.edu Center for Engineering and Innovative Design (CEID) ceid.yale.edu AND MORE 13

14 How to Get Started: Workshops Business of Biotech November 16, 5:30-7:30pm Tech Transfer IP & Licensing Location: Alexion, 100 College St 14